Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARX517 |
Synonyms | |
Therapy Description |
ARX517 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against PSMA linked to pAF-AS269, which targets the anti-microtubule agent to PSMA-expressing cells, potentially resulting in apoptosis of PSMA-positive tumor cells (Cancer Res 2022;82(12_Suppl):Abstract nr CT211; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARX517 | ARX 517|ARX-517 | PSMA Antibody 20 | ARX517 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against PSMA linked to pAF-AS269, which targets the anti-microtubule agent to PSMA-expressing cells, potentially resulting in apoptosis of PSMA-positive tumor cells (Cancer Res 2022;82(12_Suppl):Abstract nr CT211; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04662580 | Phase I | ARX517 | ARX517 in Subjects With Advanced Solid Tumor (ARX517) | Recruiting | USA | 0 |